ALZN - Alzamend Neuro Inc Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ALZN

ALZAMEND NEURO INC

NASDAQ

$1.34

▼ DOWN 2.19% (-0.03)

KEY STATISTICS

Market Cap$4.98 M

52w High$2.68

52w Low$0.84

Dividend Yield—

Frequency—

P/E-0.58

Volume6.96K

Shares Out.4.83M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Stephan Jackman

COMPENSATION 2026

Salary$350,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$18,288

Total$468,288

ABOUT

SECTOR

Healthcare

WENT PUBLIC

June 15, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateDec 8, 2026

DayTuesday

Rev. Est.—

DEC

TUE

SPLIT RECORD

DATE	TYPE	RATIO
2025-05-12	Reverse	1:9
2024-07-16	Reverse	1:10
2023-10-31	Reverse	1:15

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

VXF

0.00%

7.6K

PRICE

$1.34 ▼ DOWN 2.19% (−$0.03)

OVERLAYS

About Alzamend Neuro Inc

https://www.alzamend.com ↗

Alzamend Neuro, Inc. is a clinical-stage biopharma developing treatments for neurodegenerative and psychiatric disorders, with products like AL001 in Phase II for conditions including Alzheimer's and bipolar disorder, and AL002 in preclinical stages.

INDUSTRY

Biotechnology

A PRODUCT ALZAMEND NEURO INC IS KNOWN FOR

AL001

AL001, Alzamend Neuro's lead clinical-stage ionic cocrystal of lithium, is in Phase II trials for treating Alzheimer's, Bipolar Disorder, Major Depressive Disorder, and PTSD, aiming for improved brain delivery and fewer side effects.

COMPETITORS

COMPETITOR

Alzamend Neuro in 2025

SENTIMENT: + POSITIVE

INNOVATION · NOVEMBER 2025

Alzamend Neuro Completes Clinical Portion of Phase II 'Lithium in Brain' Study for Lead Candidate AL001

Alzamend Neuro announced the completion of the clinical phase of its first Phase II study for AL001 in healthy human subjects. This trial is significant as it compares the delivery of lithium to the brain by AL001 against a marketed lithium carbonate product, with topline data expected in the first quarter of 2026.

PRODUCT STRATEGY · Q2 2025 · IN PROGRESS

Alzamend Neuro Accelerates Clinical Development with Initiation of Five Phase II Trials for Lead Drug Candidate AL001

In 2025, Alzamend Neuro made a significant strategic shift by launching a comprehensive Phase II clinical trial program for its lead drug candidate, AL001, a novel lithium-based treatment for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD. This pivotal decision moves their core product into a critical stage of development, representing a major investment in their primary asset.